Takeda’s new lung cancer drug ‘Exkivity’ is coming to Korea.

According to industry sources, Takeda Pharmaceuticals Korea recently submitted an application for the marketing authorization of ‘Exkivity (mobocertinib).’ The drug is expected to be approved within the year at the earliest.

Exkivity was approved in the US in September last year as a non-small cell lung cancer (NSCLC) treatment that targets EGFR Exon20 insertion mutations like Janssen’s ‘Ryvrevant (amivantamab)’ that was approved last month.

Unlike Exkivity, Ryvrevant has the strength of being an oral tablet. Exkivity was granted priority review and received Breakthrough Therapy Designation, Fast Track